News

PRESS RELEASES

Read the latest updates and announcements from ITF Therapeutics.

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT^™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy

ITF Therapeutics LLC anuncia la disponibilidad comercial de DUVYZAT^™ (givinostat) en los EE. UU. para el tratamiento de pacientes con distrofia muscular de Duchenne

Italfarmaco Receives FDA Approval for Duvyzat^™ (givinostat) in Duchenne Muscular Dystrophy

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology

Publications

Learn more about our research in rare diseases.

Muscular Dystrophy Association Clinical & Scientific Conference 2024

Givinostat study in DMD: supportive results

Givinostat effects on DMD pathogenesis

For the Media

USA

Media inquiries: Brian Connor | +1 212 253 8881 | bconnor@berrypr.com
Other inquiries: Patient Advocacy and Communications Lead USA | c.allen@itftherapeutics.com

Global

Media inquiries: Charlotte Spitz or Jacob Verghese | +49 (0)151 7441 6179 | italfarmaco@trophic.eu
Other inquiries: Patient Advocacy and Communications Lead | s.parker@italfarmacogroup.com